David J. Behm
Department of Vascular Biology
Cardiovascular and Urogenital Diseases Centre of Excellence for Drug Discovery
GlaxoSmithKline
P.O. Box 1539 709 Swedeland Road
USA
Name/email consistency: high
- Inhibitory effects of putative peptidic urotensin-II receptor antagonists on urotensin-II-induced contraction of cat isolated respiratory smooth muscle. Behm, D.J., Ao, Z., Camarda, V., Aiyar, N.V., Johns, D.G., Douglas, S.A. Eur. J. Pharmacol. (2005)
- Urotensin-II: a novel systemic hypertensive factor in the cat. Behm, D.J., Doe, C.P., Johns, D.G., Maniscalco, K., Stankus, G.P., Wibberley, A., Willette, R.N., Douglas, S.A. Naunyn Schmiedebergs Arch. Pharmacol. (2004)
- Differential agonistic and antagonistic effects of the urotensin-II ligand SB-710411 at rodent and primate UT receptors. Behm, D.J., Herold, C.L., Camarda, V., Aiyar, N.V., Douglas, S.A. Eur. J. Pharmacol. (2004)
- Deletion of the UT receptor gene results in the selective loss of urotensin-II contractile activity in aortae isolated from UT receptor knockout mice. Behm, D.J., Harrison, S.M., Ao, Z., Maniscalco, K., Pickering, S.J., Grau, E.V., Woods, T.N., Coatney, R.W., Doe, C.P., Willette, R.N., Johns, D.G., Douglas, S.A. Br. J. Pharmacol. (2003)
- Pharmacological characterization of SB-710411 (Cpa-c[D-Cys-Pal-D-Trp-Lys-Val-Cys]-Cpa-amide), a novel peptidic urotensin-II receptor antagonist. Behm, D.J., Herold, C.L., Ohlstein, E.H., Knight, S.D., Dhanak, D., Douglas, S.A. Br. J. Pharmacol. (2002)
